DK3458448T3 - Fasn-inhibitorer til anvendelse til behandling af non-alkoholisk steatohepatitis - Google Patents
Fasn-inhibitorer til anvendelse til behandling af non-alkoholisk steatohepatitis Download PDFInfo
- Publication number
- DK3458448T3 DK3458448T3 DK17790287.1T DK17790287T DK3458448T3 DK 3458448 T3 DK3458448 T3 DK 3458448T3 DK 17790287 T DK17790287 T DK 17790287T DK 3458448 T3 DK3458448 T3 DK 3458448T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- alcoholic steatohepatitis
- phase inhibitors
- inhibitors
- phase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662327167P | 2016-04-25 | 2016-04-25 | |
| PCT/US2017/029469 WO2017189613A1 (en) | 2016-04-25 | 2017-04-25 | Methods of using fasn inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3458448T3 true DK3458448T3 (da) | 2021-08-23 |
Family
ID=60157111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17790287.1T DK3458448T3 (da) | 2016-04-25 | 2017-04-25 | Fasn-inhibitorer til anvendelse til behandling af non-alkoholisk steatohepatitis |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20170312273A1 (da) |
| EP (1) | EP3458448B1 (da) |
| DK (1) | DK3458448T3 (da) |
| ES (1) | ES2886935T3 (da) |
| MA (1) | MA45047A (da) |
| PL (1) | PL3458448T3 (da) |
| PT (1) | PT3458448T (da) |
| TW (1) | TW201737943A (da) |
| WO (1) | WO2017189613A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191860T1 (hr) | 2013-03-13 | 2019-12-27 | Forma Therapeutics, Inc. | Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| WO2020092395A1 (en) | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE |
| WO2020092376A1 (en) * | 2018-10-29 | 2020-05-07 | Forma Therapeutics, Inc. | Treating non-alcoholic steatohepatitis (nash) |
| CN113265468B (zh) * | 2021-07-21 | 2021-10-12 | 北京大学第三医院（北京大学第三临床医学院） | 一种与宫颈癌诊断、治疗和预后相关的miRNA |
| WO2023086483A1 (en) * | 2021-11-11 | 2023-05-19 | Sagimet Biosciences Inc. | Methods for prediction of treatment response in non-alcoholic fatty liver disease |
| JP7814782B2 (ja) * | 2021-11-29 | 2026-02-17 | オーシャン ユニバーシティ オブ チャイナ | イミダゾチアゾール誘導体およびその製造方法と使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| EP2132565A2 (en) * | 2007-02-27 | 2009-12-16 | Fasgen Diagnostics, LLC | Fatty acid synthase in liver disease |
| HRP20191860T1 (hr) * | 2013-03-13 | 2019-12-27 | Forma Therapeutics, Inc. | Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka |
| ES2634875T3 (es) | 2013-03-21 | 2017-09-29 | Merck Patent Gmbh | Derivados de piperazina como inhibidores de FASN |
| US9562035B2 (en) * | 2013-12-03 | 2017-02-07 | Janssen Pharmaceutica Nv | Benzamide derivative useful as FASN inhibitors for the treatment of cancer |
| JP6617106B2 (ja) * | 2013-12-17 | 2019-12-04 | ヤンセン ファーマシューティカ エヌ．ベー． | 癌の治療用のｆａｓｎ阻害剤として有用なイミダゾリン−５−オン誘導体 |
-
2017
- 2017-04-25 WO PCT/US2017/029469 patent/WO2017189613A1/en not_active Ceased
- 2017-04-25 EP EP17790287.1A patent/EP3458448B1/en active Active
- 2017-04-25 ES ES17790287T patent/ES2886935T3/es active Active
- 2017-04-25 US US15/497,125 patent/US20170312273A1/en not_active Abandoned
- 2017-04-25 TW TW106113737A patent/TW201737943A/zh unknown
- 2017-04-25 PT PT177902871T patent/PT3458448T/pt unknown
- 2017-04-25 MA MA045047A patent/MA45047A/fr unknown
- 2017-04-25 PL PL17790287T patent/PL3458448T3/pl unknown
- 2017-04-25 DK DK17790287.1T patent/DK3458448T3/da active
-
2019
- 2019-08-20 US US16/545,339 patent/US20190374536A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2886935T3 (es) | 2021-12-21 |
| EP3458448B1 (en) | 2021-06-23 |
| EP3458448A4 (en) | 2019-04-17 |
| PT3458448T (pt) | 2021-09-10 |
| PL3458448T3 (pl) | 2021-12-06 |
| WO2017189613A1 (en) | 2017-11-02 |
| US20190374536A1 (en) | 2019-12-12 |
| TW201737943A (zh) | 2017-11-01 |
| MA45047A (fr) | 2019-03-27 |
| EP3458448A1 (en) | 2019-03-27 |
| US20170312273A1 (en) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3501542T3 (da) | Esketamin til behandling af depression | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3445767T3 (da) | Makrocykliske mcl1-inhibitorer til behandling af cancer | |
| DK3286181T3 (da) | Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
| DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3435996T3 (da) | Elafibranor til anvendelse i behandlingen af primær biliær cholangitis | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3484423T3 (da) | Anordning til hypertermisk behandling af kløe |